

Molecular Cancer Therapeutics

A Journal of the American Association for Cancer Research

Volume 7, Number 4

April 2008

Spotlight on Clinical Response

- BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors**737
Udai Banerji, Annette Affolter, Ian Judson, Richard Marais, and Paul Workman

Review

- Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics**740
Annamaria Hadnagy, Raymond Beaulieu, and Danuta Balicki

Research Articles: Therapeutics, Targets, and Development

- Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor- κ B, p53, bax, and p27 levels**749
Catherine A. Tucker, Anita I. Kapanen, Ghania Chikh, Brad G. Hoffman, Alastair H. Kyle, Ian M. Wilson, Dana Masin, Randy D. Gascoyne, Marcel Bally, and Richard J. Klasa

- MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity *in vitro* and *in vivo***759
Marielle Fournel, Claire Bonfils, Yu Hou, Pu Theresa Yan, Marie-Claude Trachy-Bourget, Ann Kalita, Jianhong Liu, Ai-Hua Lu, Nancy Z. Zhou, Marie-France Robert, Jeffrey Gillespie, James J. Wang, H el ene Ste-Croix, Jubrail Rahil, Sylvain Lefebvre, Oscar Moradei, Daniel Delorme, A. Robert MacLeod, Jeffrey M. Besterman, and Zuomei Li

- Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia**769
C. James Chou, Michelle E. Farkas, Sherry M. Tsai, David Alvarez, Peter B. Dervan, and Joel M. Gottesfeld

- Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models**779
Yasushi Sasaki, Hideaki Negishi, Masashi Idogawa, Hiromu Suzuki, Hiroaki Mita, Minoru Toyota, Yasuhisa Shinomura, Kohzoh Imai, and Takashi Tokino

- Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma**788
Nathan R. Miselis, Zhijian J. Wu, Nico Van Rooijen, and Agnes B. Kane

contents continued

Sensitizing estrogen receptor–negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor	800
Shu-Chuan Weng, Yoko Kashida, Samuel K. Kulp, Dasheng Wang, Robert W. Brueggemeier, Charles L. Shapiro, and Ching-Shih Chen	
2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition	809
Diansheng Zhong, Xiuju Liu, Katherine Schafer-Hales, Adam I. Marcus, Fadlo R. Khuri, Shi-Yong Sun, and Wei Zhou	
Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy	818
Cathy Zhang, Karen Lundgren, Zhengming Yan, Maria E. Arango, Sharon Price, Andrea Huber, Joseph Higgins, Gabriel Troche, Judith Skaptason, Tatiana Koudriakova, Jim Nonomiya, Michelle Yang, Patrick O'Connor, Steve Bender, Gerrit Los, Cristina Lewis, and Bart Jessen	
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis	829
Davide Melisi, Satoshi Ishiyama, Guido M. Scwabas, Jason B. Fleming, Qianghua Xia, Giampaolo Tortora, James L. Abbruzzese, and Paul J. Chiao	
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma	841
Jack S. Chen, Linda J. Zhou, Michal Entin-Meer, Xiaodong Yang, Mila Donker, Zachary A. Knight, William Weiss, Kevan M. Shokat, Daphne Haas-Kogan, and David Stokoe	
Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature	851
Lin Cao, Pan Du, Shu-Han Jiang, Guang-Hui Jin, Qi-Lai Huang, and Zi-Chun Hua	
Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis	862
Jorge L. Martínez-Torrecuadrada, Lawrence H. Cheung, Paula López-Serra, Rodrigo Barderas, Marta Cañamero, Sergio Ferreira, Michael G. Rosenblum, and J. Ignacio Casal	
The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor	874
Nadia Godin-Heymann, Lindsey Ulkus, Brian W. Brannigan, Ultan McDermott, Jennifer Lamb, Shyamala Maheswaran, Jeffrey Settleman, and Daniel A. Haber	
The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex–interactive agents	880
Daekyu Sun, Wei-Jun Liu, Kexiao Guo, Jadrian J. Rusche, Scot Ebbinghaus, Vijay Gokhale, and Laurence H. Hurley	

Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells	890
Grazia Ambrosini, Haider S. Cheema, Sharon Seelman, Allison Teed, Elliot B. Sambol, Samuel Singer, and Gary K. Schwartz	
Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells	897
Deepika Dhawan, Antonella Borgatti Jeffreys, Rong Zheng, Jane C. Stewart, and Deborah W. Knapp	
UBE1L represses PML/RARα by targeting the PML domain for ISG15ylation	905
Sumit J. Shah, Steven Blumen, Ian Pitha-Rowe, Sutisak Kitareewan, Sarah J. Freemantle, Qing Feng, and Ethan Dmitrovsky	
Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells	915
Maria Serova, Aida Ghoul, Karim A. Benhadji, Sandrine Faivre, Christophe Le Tourneau, Esteban Cvitkovic, Francois Lokiec, Janet Lord, Steven M. Ogbourne, Fabien Calvo, and Eric Raymond	
SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome	923
Xuefei Cao, Carlos Clavijo, Xu Li, H. Helen Lin, Yuan Chen, Hsiu-Ming Shih, and David K. Ann	
Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines	935
Joel Greshock, Jie Cheng, David Rusnak, Anne Marie Martin, Richard Wooster, Tona Gilmer, Kwan Lee, Barbara L. Weber, and Tal Zaks	
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy	944
Judith A. Gilbert, Matthew P. Goetz, Carol A. Reynolds, James N. Ingle, Karin F. Giordano, Vera J. Suman, Hilary E. Blair, Robert B. Jenkins, Wilma L. Lingle, Monica M. Reinholz, Alex A. Adjei, and Matthew M. Ames	
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras	952
Yanan Yang, Marie Wislez, Nobukazu Fujimoto, Ludmila Prudkin, Julie G. Izzo, Futoshi Uno, Lin Ji, Amy E. Hanna, Robert R. Langley, Diane Liu, Faye M. Johnson, Ignacio Wistuba, and Jonathan M. Kurie	
Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism	961
Minsub Shim and Thomas E. Eling	
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes	972
Ronald A. Lubet, Eva Szabo, Konstantin Christov, Ann M. Bode, Marna E. Ericson, Vernon E. Steele, M. Margaret Juliana, and Clinton J. Grubbs	


WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells980
Andrew R. Cuddihy, Farid Jalali, Carla Coackley, and Robert G. Bristow

Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53993
Stéphane Supiot, Richard P. Hill, and Robert G. Bristow

Correction

Article on TRPV6 in Breast Cancer1000

On the Cover



(A) Tumor spheroids isolated from eGFP mice exposed to CM-DiI-labeled liposomes or PBS show eGFP-expressing stromal cells (green fluorescence), cells that have endocytosed CM-DiI-labeled liposomes (red fluorescence), and a subpopulation of host stromal cells that uptake liposomes (yellow or orange fluorescence, arrows). (B) Tumor spheroids from C57Bl/6 mice exposed to CM-DiI-labeled liposomes or PBS and labeled for expression of the macrophage marker CD68 (green fluorescence) show colocalization of CM-DiI and CD68 (yellow or orange fluorescence, arrows). (C) Spheroids exposed as described in (B) and labeled for the dendritic cell marker CD11c (green fluorescence, arrows) show no colocalization. D. CM-DiI-labeled or unlabeled macrophages were treated with CLIP or PLIP and the conditioned medium was transferred to cultures of mesothelioma cells. Cells incubated in conditioned medium from CM-DiI-labeled CLIP-treated macrophages (left, arrows); cells incubated in conditioned medium from CM-DiI-labeled, PLIP-treated macrophages (middle) or unlabeled, CLIP-treated macrophages (right). All cells were counterstained with DAPI (blue nuclear fluorescence). For details, see Miselis et al. in this issue.